Genetic Technologies Ltd. (GENE) Keeps The Wins Coming
Genetic Technologies Ltd. (GENE) Keeps The Wins Coming
Genetic Technologies Ltd. (NASDAQ: GENE) is a promising Australian biotech player that has made remarkable strides in the realm of genetic testing and risk identification. The potential this domain has to offer the wider healthcare sector is enormous. Recent developments have put this already winning player in the market spotlight.
基因科技有限公司（NASDAQ: GENE）是一個有前途的澳大利亞生物技術公司，在基因檢測和風險識別領域取得了顯著進步。這個領域提供更廣泛的醫療保健領域的潛力是巨大的。最近的發展已經使這個已經獲勝的球員成為市場焦點。
Generic Technologies Announces Groundbreaking Partnership
通用科技宣佈突破性合作夥伴
This week the stock for Genetic Technologies Ltd. (GENE) saw a sizeable jump from $0.83 to over $1 following positive news from the company. The company officially stated that it will be entering into a strategic alliance with Qiagen NV (QGEN), and together would build a Center of Excellency within Australia. Qiagen is a giant Dutch-based bio-molecular company that could bring tremendous value to GENE. Synergistic benefits aside, Genetic Technologies could gain substantial market exposure moving forward, while also benefitting over the long term through innovation within the partnership. Moreover, GENE also stands to see significant value addition through automation, in which QGEN holds operational expertise in.
基因技術有限公司（GENE）的股票在公司的積極消息之後，本週的股票從 0.83 美元到超過 $1。該公司正式表示，將與 QGEN NV（QGEN）建立戰略聯盟，並共同在澳大利亞建立卓越中心。Qiagen 是一家巨大的荷蘭生物分子公司，可以為 GENE 帶來巨大的價值。除了協同效益外，遺傳技術還可以獲得可觀的市場曝光率，同時還可以通過合作夥伴關係中的創新從長期受益。此外，GENE 還可以通過自動化看到顯著的增值，其中 QGEN 擁有運營專業知識。
GENE Remains Strong on the Financial Front
基因在財務方面保持強勁
In addition to the recent stellar developments announced by GENE, its performance on the financial domain remains just as impressive. It recently announced the results for its December quarter, denoting its sixth consecutive quarter of annual growth against the prior year. Its receipts from customers grew by 32% in 12 months, amounting to $2.4 million. A core driver of this excellent top-line performance relates to its improvement in the supply chain aspect of the business. In particular, the new distribution channels running in the United States have fundamentally strengthened GENE's sales to American customers.
除了 GENE 最近宣布的出色發展之外，其在金融領域的表現仍然同樣令人印象深刻。該公司最近公佈了 12 月季度的業績，表示其與上一年相比連續第六個季度的年度增長。其來自客戶的收入在 12 個月內增長了 32%，達 240 萬美元。這種卓越的頂級業績的核心驅動因素與其在業務供應鏈方面的改善有關。特別是，在美國運行的新分銷渠道從根本上加強了 GENE 對美國客戶的銷售。
Conclusion
结论
GENE seems to have quite a bright future, with positive news coming from all sides. Its financial prowess continues to flex muscles, while the company announces major partnerships with top global players, which are sure to bring value to its prospects. Shareholders can remain content with this winning pick.
GENE 似乎有一個相當光明的未來，各方都有積極的消息。其財務實力繼續彎曲肌肉，而該公司宣布與全球頂級企業的主要合作夥伴關係，這些合作夥伴關係肯定會為其前景帶來價值。股東可以通過此獲勝選擇保持內容。